Voskuil Jan L A, Bandrowski Anita, Begley C Glenn, Bradbury Andrew R M, Chalmers Andrew D, Gomes Aldrin V, Hardcastle Travis, Lund-Johansen Fridtjof, Plückthun Andreas, Roncador Giovanna, Solache Alejandra, Taussig Michael J, Trimmer James S, Williams Cecilia, Goodman Simon L
Aeonian Biotech Ltd , Marcham, UK.
Center for Research in Biological Systems, University of California , La Jolla, CA, USA.
MAbs. 2020 Jan-Dec;12(1):1794421. doi: 10.1080/19420862.2020.1794421.
In the wake of the reproducibility crisis and numerous discussions on how commercially available antibodies as research tool contribute to it, The Antibody Society developed a series of 10 webinars to address the issues involved. The webinars were delivered by speakers with both academic and commercial backgrounds. This report highlights the problems, and offers solutions to help the scientific community appropriately identify the right antibodies and to validate them for their research and development projects. Despite the various solutions proposed here, they must be applied on a case-by-case basis. Each antibody must be verified based on the content of the product sheet, and subsequently through experimentation to confirm integrity, specificity and selectivity. Verification needs to focus on the precise application and tissue/cell type for which the antibody will be used, and all verification data must be reported openly. The various approaches discussed here all have caveats, so a combination of solutions must be considered.
在可重复性危机以及众多关于市售抗体作为研究工具如何导致这一危机的讨论之后,抗体协会举办了一系列10场网络研讨会来解决其中涉及的问题。这些网络研讨会由具有学术和商业背景的演讲者进行。本报告突出了问题,并提供了解决方案,以帮助科学界正确识别合适的抗体,并为其研发项目验证这些抗体。尽管这里提出了各种解决方案,但必须根据具体情况逐一应用。每种抗体都必须根据产品说明书的内容进行验证,随后通过实验来确认其完整性、特异性和选择性。验证需要关注抗体将用于的精确应用以及组织/细胞类型,并且所有验证数据都必须公开报告。这里讨论的各种方法都有局限性,因此必须考虑多种解决方案的组合。